Devika Govind Das
University of Alabama at Birmingham
17 Papers
11 Citations
Devika Govind Das is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 5 publications.
Chat about Author
Papers
Spotlight on International Quality: COVID-19 and Its Impact on Quality Improvement in Cancer Care.
Douglas W. Blayney,Giovanni Bariani,Devika Govind Das,Shaheenah Dawood,Michael Gnant,Roselle De Guzman,S Eric Martin,Deirdre O'Mahony,Alex Roach,Paul Ruff,Carlos Sampaio,Jose Angel Sanchez,Verna Vanderpuye,Arif H. Kamal,Carolyn Hendricks +14 more
- 29 Oct 2021
TL;DR: The impact of the COVID-19 pandemic on cancer care and quality improvement has been and will continue to be felt across the globe, but this report aims to share these experiences and learnings and to assist ASCO's international members and our global fight against the pandemic and cancer as discussed by the authors.
7
International Perspective on the Pursuit of Quality in Cancer Care: Global Application of QOPI and QOPI Certification
Douglas W. Blayney,Nafisa Albdelhafeez,Abdul Rahman Jazieh,Carlos Frederico Pinto,Adrian Udrea,Alex Roach,Devika Govind Das,Stephen Grubbs,John Hamm,Mohammad Jahanzeb,Arif H. Kamal,Ronan J. Kelly,S Eric Martin,Deirdre O'Mahony,Walter Birch,Ronda Bowman,Stephanie Crist,Amy Evers,Terry Gilmore,Meredith Klein,Robert Siegel +20 more
- 06 May 2020
Racial disparities in cancer clinical trials.
TL;DR: This work has shown that cancer-related mortality has been found to be disproportionately higher in racial minorities and medically underserved populations and this necessitates adequate representation of these populations in the medical literature.
Non-small cell lung cancer in the era of immunotherapy.
Quillan Huang,Jan Ole Kemnade,Loraine Cornwell,Farrah Kheradmand,Anita L. Sabichi,Devika Govind Das +5 more
TL;DR: Current data and indications for immunotherapy in NSCLC are reviewed, new areas of research within immunotherapy are introduced, and its applicability to the Veteran population is discussed.
4